# A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II

> **NCT05055258** · PHASE2 · TERMINATED · sponsor: **KalVista Pharmaceuticals, Ltd.** · enrollment: 33 (actual)

## Conditions studied

- Angioedema, Hereditary, Types I and II

## Interventions

- **DRUG:** KVD824
- **DRUG:** Placebo to KVD824

## Key facts

- **NCT ID:** NCT05055258
- **Lead sponsor:** KalVista Pharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-18
- **Primary completion:** 2022-10-27
- **Final completion:** 2022-10-27
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Terminated by Sponsor due to adverse events reported
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05055258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05055258, "A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05055258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*